These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32467559)

  • 1. Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors - A Post Hoc Analysis of the Prospective OSAKA Study.
    Albano L; Banas B; Lehner F; Glyda M; Viklicky O; Schleibner S; Brown M; Kamar N
    Ann Transplant; 2020 May; 25():e920041. PubMed ID: 32467559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation.
    Albano L; Banas B; Klempnauer JL; Glyda M; Viklicky O; Kamar N;
    Transplantation; 2013 Nov; 96(10):897-903. PubMed ID: 23982340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
    Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.
    Trunečka P; Klempnauer J; Bechstein WO; Pirenne J; Bennet W; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Kazeem G; Tisone G
    Ann Transplant; 2019 Jun; 24():319-327. PubMed ID: 31160549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials.
    Krämer BK; Albano L; Banas B; Charpentier B; Bäckman L; Tedesco-Silva H; Lehner F; Mondragón-Ramírez GA; Glyda M; Cassuto-Viguier E; Viklický O; Mourad G; Rigotti P; Schleibner S; Kamar N
    Transplant Proc; 2017 Nov; 49(9):2040-2049. PubMed ID: 29149958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
    Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
    Lladó L; González-Castillo A; Fabregat J; Baliellas C; Ramos E; González-Vilatarsana E; Busquets J; Xiol X
    Ann Transplant; 2019 Jan; 24():36-44. PubMed ID: 30655498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study.
    TruneČka P; Klempnauer J; Bechstein WO; Pirenne J; Friman S; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Tisone G;
    Am J Transplant; 2015 Jul; 15(7):1843-54. PubMed ID: 25707487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with deceased donor kidney transplantation in 114 patients over age 60.
    Moore PS; Farney AC; Hartmann EL; Rogers J; Doares W; Gautreaux MD; Iskandar SS; Hairston G; Adams PL; Stratta RJ
    Surgery; 2007 Oct; 142(4):514-23; discussion 523.e1-2. PubMed ID: 17950343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
    Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
    Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
    Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
    Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.
    Cabello M; García P; González-Molina M; Díez de los Rios MJ; García-Sáiz M; Gutiérrez C; López V; Sola E; Burgos D; Hernández D
    Transplant Proc; 2010 Oct; 42(8):3038-40. PubMed ID: 20970603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
    Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
    Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.